Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses grows in line with its trailing trend

Q1 FY2026 other income / expenses of $2.22M rose 10.5% year over year, in line with the +10.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 10.9% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Other income / expenses amounted to 3.6% of revenue in FY2025.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +10.5% toward the trailing-twelve-month pace of +10.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.22M-10.9% QoQ
Last fiscal yearDec 2025
$2.5M-72.6% YoY
LTMMar 2026
$10.06M+10.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.5%——
1 year-72.6%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
2.5M USD
Year-over-year change
-72.6%
4-year CAGR
+18.3%

Other Income / Expenses vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.6% is the 4th highest of 11, against a peer median of -48.9%.
  • Over three fiscal years its annual growth of +14.6% compares with a peer median of +11.8%.
BDTX Competitors
Other Income / Expenses for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$158.99M USD+525.4%+142.9%1093.5%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$10.06M USD+10.6%+14.6%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$5.44M USD-67.9%-1.8%19.3%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$4.85M USD+44.2%——
IMRXImmuneering CorporationLTM Mar 2026$4.79M USD+95.0%+39.6%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.85M USD-27.9%+11.8%1268.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$1.51M USD-146.9%+2.8%2.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$2.06M USD-113.1%—18.4%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-$2.64M USD-29.9%—5.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$5.41M USD-104.4%—9176.3%
IVAInventiva S.A.FY2025-€211.38M EUR-144.8%—4715.1%
Peer median (excluding BDTX) —-48.9%+11.8%556.4%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000070M
Cost of Revenue00437K0325K
Gross Profit00(437K)069.68M
Gross Margin————99.5%
Research & Development96.83M64.44M58.91M51.31M33.56M
Selling, General & Admin30.04M28.39M27.11M27.47M16.57M
Operating Expenses126.87M92.83M86.02M78.78M49.81M
Depreciation & Amortization205K508K437K343K325K
EBITDA(125.39M)(90.66M)(82.01M)(69.33M)22.69M
EBITDA Margin————32.4%
Operating Income(126.87M)(92.83M)(86.46M)(78.78M)19.87M
Operating Margin————28.4%
Interest Income3.46M2.03M1.92M2.18M4.06M
Interest Expense00000
Other Income / Expenses1.28M1.66M4.02M9.11M2.5M
Income Before Tax(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Pre-Tax Margin————32.0%
Income Tax Expense00000
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Net Margin————32.0%
EPS (Basic)(3.47)(2.52)(1.88)(1.27)0.39
EPS (Diluted)(3.47)(2.52)(1.88)(1.27)0.39
Weighted Avg Shares36.19M36.23M43.95M55.03M56.87M
Weighted Avg Shares (Diluted)36.19M36.23M43.95M55.03M57.56M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.